131 related articles for article (PubMed ID: 31597442)
1. IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation.
Adi D; Lu XY; Fu ZY; Wei J; Baituola G; Meng YJ; Zhou YX; Hu A; Wang JK; Lu XF; Wang Y; Song BL; Ma YT; Luo J
Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2468-2479. PubMed ID: 31597442
[TBL] [Abstract][Full Text] [Related]
2. The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL.
Nelson JK; Sorrentino V; Avagliano Trezza R; Heride C; Urbe S; Distel B; Zelcer N
Circ Res; 2016 Feb; 118(3):410-9. PubMed ID: 26666640
[TBL] [Abstract][Full Text] [Related]
3. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein.
Sorrentino V; Fouchier SW; Motazacker MM; Nelson JK; Defesche JC; Dallinga-Thie GM; Kastelein JJ; Kees Hovingh G; Zelcer N
Eur Heart J; 2013 May; 34(17):1292-7. PubMed ID: 23324548
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis of the LDL receptor-interacting FERM domain in the E3 ubiquitin ligase IDOL reveals an obscured substrate-binding site.
Martinelli L; Adamopoulos A; Johansson P; Wan PT; Gunnarsson J; Guo H; Boyd H; Zelcer N; Sixma TK
J Biol Chem; 2020 Sep; 295(39):13570-13583. PubMed ID: 32727844
[TBL] [Abstract][Full Text] [Related]
5. Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol.
Ibrahim S; Somanathan S; Billheimer J; Wilson JM; Rader DJ
Cardiovasc Res; 2016 May; 110(1):23-9. PubMed ID: 26786161
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap).
Do HT; Tselykh TV; Mäkelä J; Ho TH; Olkkonen VM; Bornhauser BC; Korhonen L; Zelcer N; Lindholm D
J Biol Chem; 2012 Apr; 287(16):12602-11. PubMed ID: 22378787
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor.
Sorrentino V; Zelcer N
Curr Opin Lipidol; 2012 Jun; 23(3):213-219. PubMed ID: 22510808
[TBL] [Abstract][Full Text] [Related]
8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P
Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
[TBL] [Abstract][Full Text] [Related]
10. IDOL, inducible degrader of low-density lipoprotein receptor, serves as a potential therapeutic target for dyslipidemia.
Zhang CP; Tian Y; Zhang M; Tuo QH; Chen JX; Liao DF
Med Hypotheses; 2016 Jan; 86():138-42. PubMed ID: 26601593
[TBL] [Abstract][Full Text] [Related]
11. Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL).
Sorrentino V; Scheer L; Santos A; Reits E; Bleijlevens B; Zelcer N
J Biol Chem; 2011 Aug; 286(34):30190-9. PubMed ID: 21734303
[TBL] [Abstract][Full Text] [Related]
12. Regulation of intestinal LDLR by the LXR-IDOL axis.
van Loon NM; van Wouw SAE; Ottenhoff R; Nelson JK; Kingma J; Scheij S; Moeton M; Zelcer N
Atherosclerosis; 2020 Dec; 315():1-9. PubMed ID: 33190106
[TBL] [Abstract][Full Text] [Related]
13. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
Zhang L; Reue K; Fong LG; Young SG; Tontonoz P
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2541-6. PubMed ID: 22936343
[TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin ligase inducible degrader of the LDL receptor/myosin light chain interacting protein in health and disease.
van Loon NM; Lindholm D; Zelcer N
Curr Opin Lipidol; 2019 Jun; 30(3):192-197. PubMed ID: 30896554
[TBL] [Abstract][Full Text] [Related]
15. SUMOylation of the ubiquitin ligase IDOL decreases LDL receptor levels and is reversed by SENP1.
Wang JQ; Lin ZC; Li LL; Zhang SF; Li WH; Liu W; Song BL; Luo J
J Biol Chem; 2021; 296():100032. PubMed ID: 33154164
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake.
Nelson JK; Cook EC; Loregger A; Hoeksema MA; Scheij S; Kovacevic I; Hordijk PL; Ovaa H; Zelcer N
J Biol Chem; 2016 Feb; 291(9):4813-25. PubMed ID: 26719329
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.
Calkin AC; Lee SD; Kim J; Van Stijn CM; Wu XH; Lusis AJ; Hong C; Tangirala RI; Tontonoz P
Circ Res; 2014 Aug; 115(4):442-9. PubMed ID: 24935961
[TBL] [Abstract][Full Text] [Related]
18. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Zelcer N; Hong C; Boyadjian R; Tontonoz P
Science; 2009 Jul; 325(5936):100-4. PubMed ID: 19520913
[TBL] [Abstract][Full Text] [Related]
19. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Liu S; Vaziri ND
Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
[TBL] [Abstract][Full Text] [Related]
20. Platycodin D enhances LDLR expression and LDL uptake via down-regulation of IDOL mRNA in hepatic cells.
Choi YJ; Lee SJ; Kim HI; Lee HJ; Kang SJ; Kim TY; Cheon C; Ko SG
Sci Rep; 2020 Nov; 10(1):19834. PubMed ID: 33199761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
